[NH:1]1[CH2:5][CH2:4][CH2:3][C:2]1=[O:6].[CH:7]1([C:10]2[C:11]([N:19]3[CH2:24][CH2:23][N:22]([C:25]([C:27]4[CH:32]=[CH:31][C:30](I)=[CH:29][C:28]=4[F:34])=[O:26])[CH2:21][CH2:20]3)=[N:12][CH:13]=[C:14]([CH:16]3[CH2:18][CH2:17]3)[CH:15]=2)[CH2:9][CH2:8]1>>[CH:7]1([C:10]2[C:11]([N:19]3[CH2:20][CH2:21][N:22]([C:25]([C:27]4[CH:32]=[CH:31][C:30]([N:1]5[CH2:5][CH2:4][CH2:3][C:2]5=[O:6])=[CH:29][C:28]=4[F:34])=[O:26])[CH2:23][CH2:24]3)=[N:12][CH:13]=[C:14]([CH:16]3[CH2:18][CH2:17]3)[CH:15]=2)[CH2:8][CH2:9]1Using pyrrolidin-2-one (35 mg) and [4-(3,5-dicyclopropylpyridin-2-yl)piperazin-1-yl](2-fluoro-4-iodophenyl)methanone (200 mg) described in Preparation Example 164 and by the reaction and treatment in the same manner as in Example 1, the title compound (115 mg) was obtained.